New gene-silencing therapy aims to lower stubborn high cholesterol
NCT ID NCT07428473
First seen Feb 23, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This early-stage study tests STX-1150, a one-time infusion that temporarily turns off a gene (PCSK9) in the liver to lower bad cholesterol (LDL-C). It does not change your DNA. About 64 adults with high LDL-C will join, and researchers will check safety and how well it works over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ELEVATED LDL-C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Monash Health/ Victorian Heart Hospital (VHH)
Clayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.